CN114469969B - Application of pulsatilla saponin B5 in preparation of skin care products - Google Patents

Application of pulsatilla saponin B5 in preparation of skin care products Download PDF

Info

Publication number
CN114469969B
CN114469969B CN202210107534.9A CN202210107534A CN114469969B CN 114469969 B CN114469969 B CN 114469969B CN 202210107534 A CN202210107534 A CN 202210107534A CN 114469969 B CN114469969 B CN 114469969B
Authority
CN
China
Prior art keywords
skin
skin care
group
saponin
care products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210107534.9A
Other languages
Chinese (zh)
Other versions
CN114469969A (en
Inventor
郭秋岩
王继刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Priority to CN202210107534.9A priority Critical patent/CN114469969B/en
Publication of CN114469969A publication Critical patent/CN114469969A/en
Application granted granted Critical
Publication of CN114469969B publication Critical patent/CN114469969B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

The invention discloses application of pulsatilla chinensis saponin B5 in preparation of skin care products. The skin care product is used for treating skin allergy and/or skin scar. Experiments show that the anemonin B5 can effectively reduce the severity of skin allergy and damaged skin scars, and the anemonin B5 can be used for preparing skin care products or medicines for treating skin allergy and/or repairing damaged skin scars.

Description

Application of pulsatilla saponin B5 in preparation of skin care products
Technical Field
The invention relates to the field of medical health, in particular to application of pulsatilla chinensis saponin B5 in preparation of skin care products.
Background
The concept of skin allergy is not completely the same in the medical field, which refers to immune-mediated skin allergy, and the incidence rate is about 15% -20% worldwide, and skin allergy phenomena include pruritus, wheal, erythema, purpura, etc. In the cosmetic field, it is referred to a highly intolerant state of the skin, which is more likely to cause skin inflammation by various stimuli due to sensitive skin with poor barrier function, such as subjective symptoms of stabbing pain, burning, tightness, itching, etc., and normal skin appearance or mild erythema, desquamation and dryness.
The diseases mainly characterized by the damaged scars of the skin mainly comprise mechanical wounds, burns and scalds, bedsores, chronic lower treatment ulcers, diabetic feet, cancerous ulcers and the like, and are intractable diseases recognized in the medical field due to the long course of the damaged skin and the difficult recovery of the state of the disease. The common preparations for traumatology have the disadvantages of slow effect, difficult scabbing and healing, long course of disease and the like. At present, the hemostatic or blood-activating medicament and the antibacterial medicament are mainly used together, but the effect is not good enough.
At present, skin care products capable of treating skin allergy and repairing damaged scars of the skin are rare, so that a skin care product which has good safety, good curative effect and quick response and can treat skin allergy and repair damaged scars of the skin at the same time is urgently needed.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the application of the pulsatilla saponin B5 in the preparation of skin care products.
Pulsatillae saponin B5 with molecular formula of C 59 H 98 O 26 The molecular weight is 1223.41, and the structure is shown in formula (I):
Figure BDA0003493897980000021
further, the skin care product is a skin care product for treating skin allergy and/or skin scar.
The invention also provides a skin care product, which comprises the pulsatilla saponin B5.
Further, the skin care product is a skin care product for treating skin allergy.
Furthermore, the skin care product is a skin care product for treating skin scars.
Further, the skin care product further comprises one or more auxiliary agents selected from the group consisting of an excipient, a humectant, a nutrition enhancer, a preservative, a pH buffer, a thickener, a chelating agent, and a solubilizing agent. The excipient is preferably petrolatum.
Further, the skin care product is selected from any one of cream, emulsion, essence, oil, lotion, body lotion, bath, eye skin care, pack, and face wash.
The invention also provides a skin care medicine, which comprises pulsatilla saponin B5.
Furthermore, the medicine and the skin care product are both external medicines and daily chemical products, and the using concentration of the medicine and the skin care product is 1.0-1.5mg/mL, and preferably 1.25 mg/mL.
The invention also provides the application of the skin care product and the skin care medicament in skin care.
In summary, compared with the prior art, the invention achieves the following technical effects:
(1) pulsatillae saponin B5 has effect of relieving skin allergy.
(2) Pulsatillae saponin B5 has effect of repairing damaged skin scar.
(3) By using the pulsatilla chinensis saponin B5, the weight of a rat is not reduced, which shows that pulsatilla chinensis saponin B5 has no toxic or side effect and does not have the problem of safety.
(4) The medicine can be taken continuously for 7 days, the effect is fast, and the treatment period is short.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained according to the drawings without inventive efforts.
FIG. 1 is a photograph of the skin of each group of mice after UV irradiation in example 1 of the present invention.
FIG. 2 is a graph showing the skin allergy severity score of each group of mice after UV irradiation in example 1 of the present invention.
Figure 3 is a graph showing the skin scar of the rats in each group according to example 2 of the present invention.
Figure 4 is a severity score for damaged skin scar in each group of rats of example 2 of the present invention.
FIG. 5 shows the statistical results of the body weights of the rats in each group in example 2 of the present invention.
Detailed Description
In order to make the technical solutions of the present invention better understood, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without making creative efforts based on the embodiments in the present invention, shall fall within the protection scope of the present invention.
Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Example 1 evaluation of efficacy of Pulsatillae saponin B5 in relieving skin allergy
(1) Group arrangement
Model group, vaseline group, anemonin B5 group, and zinc oxide group.
(2) Laboratory animal
Beijing west mountain Changyang farm, Kunming mouse, female, 18-20g, common grade, production license number: SYXK2016 (Kp) -0034. The animal is bred in the experimental animal center of the institute of basic theory of traditional Chinese medicine of Chinese academy of sciences, and the license number is SYXK (Jing) 2016-0021.
(3) Experimental methods
32 female mice were weighed and numbered, and randomly divided into a model group, a vaseline group (vaseline was used as a control to exclude interference with drug efficacy because the drug used was a dissolution base, and thus was set as a control), a anemonin B5 group (1.0-1.5mg/mL was effective, and the concentration used in this example was 1.25mg/mL), and a zinc oxide ointment group (positive drug, Guangdong Hengjian pharmaceutical Co., Ltd., 210502), each group consisting of 8 mice.
Approximately 24 hours before the test, the spine of the back of the animal is sheared off, the skin is exposed, and the hair removing range is 4 multiplied by 6 cm. Each group of mice was then uv-irradiated for 1 hour per day, resulting in a mouse skin allergy model. After the ultraviolet irradiation is finished, 1mL of the corresponding test agent is smeared on the skin of the mouse, the smearing area is 3X 5cm, and an equal amount of vaseline is smeared on a vaseline group to serve as a control. The molding and administration were continued for 7 days. And (5) observing the skin allergy condition of each group of mice after the experiment is finished, and grading according to a grading standard.
(4) Skin severity scoring criteria
1. The skin is hard-surfaced and hair does not grow. (0-0.5-1 points are given depending on the severity from light to heavy).
2. The skin is red and swollen, and has the phenomena of ulceration, tissue fluid discharge and the like. (0-0.5-1 points are given depending on the severity from light to heavy).
3. The scabbing phenomenon on the surface of the skin, wherein more than half of the administration area is 1 minute, and less than half is 0.5 minute;
scattered, incomplete and crusted skin, large distribution area of 1 point, and 0.5 point of abscission.
4. The skin surface color was uneven, 0.5 points, with black spots, cracks, multiple bleeding spots, etc., 1 point.
5. Wrinkles appear on the surface of the skin, and are classified according to depth, density and hardness. (0-0.5-1 points are given depending on the severity from light to heavy).
The above scores are summed up to be the final score of the skin severity score.
(5) Results of the experiment
As shown in fig. 1 and 2, the skin severity of the mice in the petrolatum group was not significantly improved compared to the model group, indicating that the dissolved matrix of the drug, petrolatum, did not affect the efficacy evaluation of the drug; compared with a model group, the pulsatilla chinensis saponin B5 group and the positive drug zinc oxide group can effectively improve the skin allergy severity of allergic mice (P is less than 0.05), wherein the data of pulsatilla chinensis saponin B5 have statistical difference, and the drug effect of pulsatilla chinensis saponin B5 is basically the same as that of zinc oxide. The above results indicate that the pulsatilla saponin B5 has the effect of relieving skin allergy.
Example 2 evaluation of drug efficacy of Pulsatillae saponin B5 in repairing scar on damaged skin
(1) Group arrangement
Model group, vaseline group (vaseline was used as a dissolution matrix for the drug and was set as a control to exclude interference with drug effect), anemonin B5 group (1.0-1.5mg/mL was effective, and the concentration used in this example was 1.25mg/mL), and positive drug-bamboo erythromycin ointment group (Yunnan botanical drug industries, Ltd., 20201204).
(2) Laboratory animal
Beijing west Shanchang Yangyang, SD rat, female, 200-: SYXK2016 (Kyoto) -0034. The animal is bred in the experimental animal center of the institute of basic theory of traditional Chinese medicine of Chinese academy of sciences, and the license number is SYXK (Jing) 2016-0021.
(3) Experimental methods
Weighing 32 female rats, numbering, and randomly dividing into model group, vaseline group, anemonin B5 group, and positive medicinal bamboo erythromycin ointment group, wherein each group contains 8 rats. Except for the model group, the drug was administered 2 times per day (the prepared drug was applied directly to the skin at the scratched portion).
Electrically pushing and shaving off back hair by 5 x 5cm for pets, brushing the scratch area of the sharp iron steel brush on the back of a rat by about 3 x 3cm for 20 times respectively in the upper, lower, left and right sides of the skin range to break the skin and seep blood, then randomly grouping, starting administration on the next day for 7 days, and observing whether erythema and edema exist at the administration part of the skin and the recovery condition of corresponding medicines.
(4) Scar severity scoring criteria
Figure BDA0003493897980000061
The scores for erythema and edema add up to the final score for the scar severity score.
(5) Results of the experiment
As shown in fig. 3 and 4, the severity of skin scar of the rats in the vaseline group was not significantly improved compared to the model group, indicating that the excipient did not affect the evaluation of the drug effect of the drug; compared with a model group, the pulsatilla saponin B5 group and the positive drug hypocrellin group can effectively improve the skin scar degree of rats (P is less than 0.05), wherein the data of pulsatilla saponin B5 have statistical difference; and the drug effect of the pulsatilla chinensis saponin B5 is better than that of hypocrellin. In addition, the weight data of the rats in each group has no statistical difference, which shows that the pulsatilla saponin B5 has no toxic or side effect on the rats and has no safety problem. The results show that the pulsatilla saponin B5 has the effect of repairing damaged skin scars.
By combining the above embodiments, it can be determined that the following technical effects can be achieved by using the pulsatilla saponin B5:
(1) pulsatillae saponin B5 has effect of relieving skin allergy.
(2) Pulsatillae saponin B5 has effect of repairing damaged skin scar.
(3) By using the pulsatilla saponin B5, the weight of a rat is not reduced, which shows that the pulsatilla saponin B5 has no toxic or side effect and does not have the safety problem.
(4) The medicine can be taken continuously for 7 days, the effect is fast, and the treatment period is short.
The present invention can be produced in various embodiments depending on the kind of components, content of components, dosage form, and the like. For example:
embodiment 1: a skin care product contains Pulsatillae saponin B5 as effective component;
can be made into cream, emulsion, essence, oil, cosmetic water, body refreshing, bath, eye skin caring, facial mask, and facial cleanser.
The commonly used auxiliary materials are: one or more of excipients, humectants, nutrition enhancers, preservatives, pH buffers, thickeners, chelating agents, and co-solvents.
Excipient: in addition to the main drugs, the other additives in the preparation can also be called as auxiliary materials. The excipient in the present invention is preferably vaseline.
pH regulator: to avoid excessive irritation and to improve stability, buffer solutions are commonly used to stabilize the pH of skin care products. Commonly used buffer solutions include boric acid buffer, phosphate buffer, and the like.
Thickening agent: methylcellulose (MC), polyvinyl alcohol (PVA), carbomer, povidone (PVP) and the like are commonly used, and CMC-Na is not commonly used because of incompatibility with alkaloid salt and chlorhexidine.
Embodiment 2: skin care medicine containing Pulsatillae saponin B5 as effective component;
the medicine is external medicine, such as cream, lotion, etc.
The above embodiments can be adapted to the size of the dosage in the unit product to suit different uses.
In conclusion, the invention discloses application of pulsatilla saponin B5 in preparation of skin care products. The skin care product is used for treating skin allergy and/or skin scar. Experiments show that the anemonin B5 can effectively reduce the severity of skin allergy and damaged skin scars, and the anemonin B5 can be used for preparing skin care products or medicines for treating skin allergy and/or repairing damaged skin scars.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.

Claims (1)

1. Application of pulsatilla saponin B5 as the only active ingredient in preparing skin care products for treating skin scars.
CN202210107534.9A 2022-01-28 2022-01-28 Application of pulsatilla saponin B5 in preparation of skin care products Active CN114469969B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210107534.9A CN114469969B (en) 2022-01-28 2022-01-28 Application of pulsatilla saponin B5 in preparation of skin care products

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210107534.9A CN114469969B (en) 2022-01-28 2022-01-28 Application of pulsatilla saponin B5 in preparation of skin care products

Publications (2)

Publication Number Publication Date
CN114469969A CN114469969A (en) 2022-05-13
CN114469969B true CN114469969B (en) 2022-09-27

Family

ID=81475735

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210107534.9A Active CN114469969B (en) 2022-01-28 2022-01-28 Application of pulsatilla saponin B5 in preparation of skin care products

Country Status (1)

Country Link
CN (1) CN114469969B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111249289A (en) * 2020-02-14 2020-06-09 广西英路维特药物有限公司 Oral care product or medicament for anti-inflammation and/or anti-allergy
CN113318002B (en) * 2021-06-12 2024-01-19 广西馨海药业科技有限公司 Anti-inflammatory acne-removing composition and cosmetic

Also Published As

Publication number Publication date
CN114469969A (en) 2022-05-13

Similar Documents

Publication Publication Date Title
Wölbling et al. Local therapy of herpes simplex with dried extract from Melissa officinalis
RU2671492C2 (en) Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
US10206939B2 (en) Treatment of papulopustular rosacea with ivermectin
CA2613297C (en) Composition for treating skin lesions
CN104922130B (en) It is a kind of to be used to treat gelling agent of herpes zoster and preparation method thereof
US6455565B1 (en) Method for inhibiting skin lesion formation using histamine as the active ingredient
DE69730214T2 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF HERPES SIMPLEX
CN101342174B (en) Phthiobuzonum/diclothane compound topical formulation
US11590211B2 (en) Systems for treating dermal inflammatory conditions
CN114469969B (en) Application of pulsatilla saponin B5 in preparation of skin care products
CN114452292B (en) Application of pulsatilla saponin B4 in preparation of skin care products
KR102587300B1 (en) A composition for preventing or treating for atopic dermatitis
CN1116038C (en) Exterior-applied liquid medicine for treating acne
WO2015059572A1 (en) A method for topically treating actinic keratosis with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
CN108078868A (en) A kind of antiallergic composition for skin care item
CN104042631B (en) Application of the Liushen Pills in preventing and treating Fungal Skin medicine is prepared
EP2620146A1 (en) Ibuprofen for treating actinic keratosis
CA2160779C (en) Method and composition for topical treatment of damaged tissue using histamine phosphate as active ingredient
US20170119703A1 (en) Methods of treatment of acne vulgaris using topical dapsone compositions
CN100387254C (en) Suppository of Chinese traditional medicine and preparing method
CN101766731A (en) Tea polyphenol acne resistant external preparation
KR20230039979A (en) Gel composition for preventing or treating atopic dermatitis
CN116920072A (en) Composition for treating cheilitis and stomatitis, and preparation method and application thereof
CN117085035A (en) Composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts and crafts and preparation method thereof
CN107693608A (en) A kind of Chinese and Western for treating eczema combines pharmaceutical preparation and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant